Loading...
XPAR
EQS
Market cap563mUSD
Jul 10, Last price  
33.35EUR
1D
1.83%
1Q
-15.57%
Jan 2017
-4.58%
IPO
705.56%
Name

Equasens SA

Chart & Performance

D1W1MN
XPAR:EQS chart
P/E
12.76
P/S
2.12
EPS
2.61
Div Yield, %
3.82%
Shrs. gr., 5y
0.14%
Rev. gr., 5y
6.61%
Revenues
237m
+9.09%
67,357,00070,949,00074,800,00081,621,00091,551,00097,064,000108,722,000113,407,000114,560,000113,477,000128,381,000129,669,000148,480,000158,569,000171,754,000193,069,000214,075,000219,788,000216,800,000236,500,000
Net income
39m
+8.56%
7,304,000-8,554,0009,104,0009,609,00011,040,00011,754,00013,516,00015,825,00017,011,00018,792,00020,567,00023,135,00025,432,00028,403,00030,714,00039,119,00046,376,00047,047,00036,200,00039,300,000
CFO
59m
+24.49%
8,190,00010,541,0005,464,0008,836,00012,345,00014,010,00018,053,00012,290,00016,688,00019,961,00022,601,00027,186,00028,741,00040,665,00047,208,00047,516,00056,977,00061,590,00047,554,00059,200,000
Dividend
Jul 02, 20251.25 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Equasens S.A., established in 1996 and headquartered in Villers-les-Nancy, France, delivers a diverse portfolio of information technology solutions tailored for the European healthcare industry. The company primarily equips pharmacies and their networks with advanced management systems, including LGPI global services and OffiCentral. Pharmacists leverage a comprehensive suite of tools designed to streamline daily business operations, such as OffiMSS, OffiSecure, OffiProtect, OffiPass, OffiSeen, OffiCash, Offizzy, and OffiLocker. To foster stronger customer relationships and engagement, Equasens provides innovative solutions like OffiTag, OffiTouch, OffiMédia, OffiConnect, alongside automation systems and loyalty program management. Beyond operational software, the company offers analytical insights through its My Pilot tool and professional development opportunities via OffiLearning, an e-learning platform. A key area of focus is patient support, with offerings spanning compliance monitoring software, Multimeds, Automeds, OffiTéléconsult, and essential pharmaceutical and shared medical record services. The company's specialized systems include ULTIMATE, which combines efficient pharmacy administration with enhanced patient care, and FARMACLICK, a protocol facilitating communication between pharmacies and wholesale distributors (the latter also served by DIFARM). Additional retail management tools comprise PHARE and the SOPHIA pharmacy application, complemented by OffiMédia POS displays. Equasens also addresses specific health needs, such as chronic renal failure management with eNephro, and simplifies the administration of patient education programs through TPE Pilot. Further extending its reach across the healthcare sector, Equasens offers various dedicated solutions like NOVIACARE, CARELIB (for home and nursing home care), KAPELSE, TITAN, ANTHADINE software, the MOBISOINS mobile tool, MICROSOINS for in-home nursing care, and LOGICLIC. For holistic patient journey oversight, the AXIGATE solutions and CHORUS platform are available. Supplementary services include medical telesecretarial assistance for healthcare professionals and equipment lease financing options. Equasens S.A. functions as a subsidiary of Marque Verte Sante.
IPO date
Oct 20, 2000
Employees
1,221
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT